Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics is a clinical-stage biopharmaceutical company with a vertically integrated, end-to-end 212Pb platform that has a structural advantage in its patented chelation technology and a regional manufacturing network designed to address industry competition and supply constraints. Clinical data has shown a potent alpha emission with minimal toxicity and deepening tumor reductions over time for its VMT-α-NET program, providing a favorable outlook for its three clinical-stage programs and upcoming data catalysts in 2026. The evolving NET treatment paradigm and increasing potential for earlier-line use make Perspective Therapeutics a differentiated frontrunner in the targeted alpha therapy space.

Bears say

Perspective Therapeutics is facing key risks in its pipeline programs, particularly with the delay in FDA approval for PSV359 and VMT01. The company also has a high valuation based on a sum-of-parts analysis, which could be concerning given the potential delays and uncertainties in their pipeline. Additionally, there is competition in the radiopharmaceutical market, which may limit the potential market for their targeted alpha-particle therapies.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.